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Summary
 
The frequency of clonally expanded and persistent T cells recognizing the immunodominant
autoantigenic peptide of myelin basic protein (MBP)p85-99 was directly measured ex vivo in
subjects with typical relapsing remitting multiple sclerosis (MS). T cells expressing mRNA
transcripts encoding T cell receptor (TCR)-
 
a
 
 and -
 
b
 
 chains found in T cell clones previously
isolated from these subjects recognizing the MBPp85-99 epitope were examined. In contrast to
frequencies of 1 in 10
 
5
 
–10
 
6
 
 as measured by limiting dilution analysis, estimates of the T cell fre-
quencies expressing MBPp85-99–associated TCR chain transcripts were as high as 1 in 300.
These high frequencies were confirmed by performing PCR on single T cells isolated by flow
cytometry. MBPp85-99 TCR transcripts were present in IL-2 receptor 
 
a
 
–positive T cells
which were induced to undergo Fas-mediated cell death upon antigen stimulation. These data
demonstrate that at least a subpopulation of patients with MS can have a very high frequency of
activated autoreactive T cells.
 
M
 
ultiple sclerosis (MS)
 
1
 
 is a chronic inflammatory dis-
ease characterized by lymphocytic infiltration and de-
myelination in the central nervous system (CNS) thought
to be initiated by activated T cells recognizing myelin com-
ponents of the CNS (1–5). T cells with high affinity recep-
tors recognizing myelin basic protein (MBP) and proteo-
lipid protein (PLP) are part of the normal T cell repertoire
and are present in the blood of MS patients as well as in
healthy individuals with comparable frequencies of 1 in
 
z
 
10
 
5
 
–10
 
6
 
 T cells, as revealed by limiting dilution analysis
(LDA; 6–8). However, determination of the frequency of
antigen-specific T cells in LDA assays is based upon the
ability of these cells to proliferate in response to antigen.
Thus, estimated frequencies are confounded by the need to
grow short term T cell lines and do not allow detection of
antigen-specific T cells that respond to antigen by means of
cytokine production in the absence of proliferation (9).
Moreover, investigations using cloning techniques that
preferentially allow the growth of activated T cells have
suggested that autoreactive T cells from MS patients are ac-
tivated in vivo as compared to the autoreactive T cells from
normal individuals, and that the precursor frequencies of in
vivo activated T cells responding to MBP or PLP are in fact
higher in MS patients (10, 11). Thus, different T cell clon-
ing strategies may influence the calculated frequency of au-
toreactive T cells.
The MBPp85-99 epitope is one of the immunodomi-
nant epitopes of MBP (6, 7, 12). We have previously deter-
mined the TCR sequences of clonally persistent MBPp85-
99–reactive T cells both in patients with MS and in normal
individuals (13). This enabled us to develop methods to di-
rectly estimate the frequency of MBPp85-99–reactive T cells
by measuring mRNA transcripts encoding the TCR-
 
a
 
 and
-
 
b
 
 chains ex vivo in peripheral blood without in vitro ma-
nipulation. Moreover, the ability to directly measure frequen-
cies of MBPp85-99–reactive T cells allowed us to functionally
examine the response of autoreactive T cells to antigen.
In contrast to frequencies of one in 10
 
5
 
 to 10
 
6
 
 as mea-
sured by LDA, estimates of the T cell frequencies express-
ing MBPp85-99 associated TCR chain transcripts were as
high as 1 in 300. MBPp85-99–associated TCR transcripts
were present in IL-2 receptor 
 
a
 
 (IL-2R
 
a
 
)–positive T cells
which were induced to undergo Fas-mediated cell death
upon antigen stimulation. These data demonstrate that mea-
surements of T cell frequencies by short-term T cell cloning
and thymidine incorporation, as is used by LDA, do not al-
low for correct estimates of activated antigen-reactive T
cells. Additionally, at least a subpopulation of patients with
 
1
 
Abbreviations used in this paper:
 
 CDR3, third-complementarity-determin-
ing region; CNS, central nervous system; dd, double distilled; dNTP,
deoxynucleotide triphosphate; dT, deoxythimidine; IL-2R
 
a
 
, IL-2 recep-
tor 
 
a
 
; LB, luria broth; LDA, limiting dilution analysis; MBP, myelin basic
protein; MS, multiple sclerosis; PLP, proteolipid protein; WMNC, whole
mononuclear cells.
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MS can have a very high frequency of activated autoreac-
tive T cells.
 
Materials and Methods
 
MBPp85-99–reactive T Cell Clones.
 
Investigations were approved
by the human subjects committee of the Brigham and Women’s
Hospital (Boston, MA). MBPp85-99–reactive clones from the
subjects (two patients with relapsing remitting MS and two nor-
mal control subjects) were established previously and T cell re-
ceptor sequences published (13). In brief, amino acid TCR-
 
a
 
 and
-
 
b
 
 chain junctional region sequences were as follows: patient Ob,
clone Ob.2F3 V
 
a
 
3.1-TDATSGTYKYIFGTGTRLKVLA-C
 
a
 
,
V
 
b
 
2.1-RDLTSGSLNEQFFGPGTRLTVL-C
 
b
 
; patient Hy, clone
Hy.1G11 V
 
a
 
3.1-TDTGGSYIPTFGRGTSLIVHP-C
 
a
 
, V
 
b
 
17.1-
TSGSYNEQFFGPGTRLTVL-C
 
b
 
, clone Hy.2B6 V
 
a
 
3.1-TDA-
GGQNFVFGPGTRLSVLP-C
 
a
 
, V
 
b
 
17.1-TDWSSYNEQFFGPG-
TRLTVL-C
 
b
 
, clone Hy.2E11 V
 
a
 
3.1-TDSGGSYIPTFGRGT-
SLIVHP-C
 
a
 
, V
 
b
 
4-PSGQGTYGYTFGSGTRLTVV-C
 
b
 
; control
Nb, clone Nb17.8 V
 
a
 
8-ASISDDMRFGAGTRLTVKP-C
 
a
 
, V
 
b
 
12-
YSPLGNEQFFGPGTRLTVL-C
 
b
 
; control Jl, clone NSJl5 V
 
a
 
18-
SGYNNNDMRFGAGTRLTVKP-C
 
a
 
, V
 
b
 
21-LTVGSYNEQ-
FGPGTRLTVL-C
 
b
 
, clone NSJl 14.5 V
 
a
 
18-SGSNDYKLSFG-
AGTTVTVRA-C
 
a
 
, V
 
b
 
14-SSIPGQPQHFGDGTRLSIL-C
 
b
 
. The
third complementarity-determing region (CDR3) probes were
named according to the first three amino acids in the NH
 
2
 
-termi-
nal sequence of the junctional region.
 
PCR Amplification of TCR Chains.
 
mRNA extractions were
performed using the RNAzol B method (Teltest, Inc., Friends-
wood, TX). RNA was coprecipitated with 5 
 
m
 
g of tRNA (Sigma
Chemical Co., St. Louis, MO) in isopropanol overnight at 
 
2
 
20
 
8
 
C.
After washing with 70% ethanol, pellets were air dried and resus-
pended in double distilled (dd) H
 
2
 
O. First strand cDNA synthesis
was primed with oligo(deoxythimidine; dT) in 11 
 
m
 
l reaction and
the samples heated to 70
 
8
 
C for 10 min. 4 
 
m
 
l of 5
 
3
 
 buffer, 2 
 
m
 
l
0.1M dithiothreithiol, and 1 
 
m
 
l each of 10 mM deoxynucleotide
triphosphate (dNTPs), 33 U of RNAsin, and 200 U of moloney
murine leukemia virus reverse transcriptase (all from Promega
Corp., Madison, WI) were then added. cDNA synthesis was carried
out at 42
 
8
 
C for 60 min, and ddH
 
2
 
O was added to a final volume
of 200 
 
m
 
l. 10 
 
m
 
l was used for each PCR. 50-
 
m
 
l PCR reactions
contained 0.25 
 
m
 
g of forward and reverse primer, 1U of Taq poly-
merase, and 20 
 
m
 
l of a mix containing dNTPs and Taq buffer (Per-
kin-Elmer Corp., Branchburg, NJ). Amplifications were done for 35
cycles by using the following temperature profile: 94
 
8
 
C denatur-
ation for 1 min, 60
 
8
 
C annealing for 2 min, and 72
 
8
 
C extension for
3 min with a final extension step at 72
 
8
 
C for 10 min. Sequences
of primers were: V
 
a
 
3, 5
 
9
 
 - GGA GTG TCT TTG GTG ATT
CTA TGG CTT CAA - 3
 
9
 
; V
 
a
 
8, 5
 
9
 
 - CGA GCT TTA TTT
ATG TAC TTG TGG CTG CAG - 3
 
9
 
; V
 
a
 
18, 5
 
9
 
 - TGT CAG
GCA ATG ACA AGG GAA GCA ACA AAG - 3
 
9
 
; C
 
a
 
 reverse
primer, 5
 
9
 
 - TTG TTG CTC CAG GCC ACA GCA CTG
TTG CTC - 3
 
9
 
; V
 
b
 
17.1, 5
 
9 
 
- TTT CAG AAA GGA GAT ATA
GCT GAA GGG TAC - 3
 
9
 
; C
 
b
 
 reverse primer, 5
 
9
 
- GGC AGA
CAG GAC CCC TTG CTG GTA GGA CAC -3
 
9
 
; C
 
b
 
 internal
primer: 5
 
9
 
- TGT GCA CCT CCT TCC CAT TCA CCC ACC
AGC - 3
 
9
 
; Amplified products were analyzed on 1% agarose gels
stained with ethidium bromide.
 
Colony Hybridization.
 
PCR products were purified using PCR
purification system (Promega Corp.). Purified PCR reactions
were ligated into pCRII vectors (TA cloning system; Invitrogen,
San Diego, CA) in the presence of T4 ligase by incubation at
14
 
8
 
C overnight. 50 
 
m
 
l of competent bacteria (INV
 
a
 
F
 
9
 
; Invitro-
gen) were then transformed with ligation products and screened for
inserts on X-galactosidase–ampicillin containing luria broth (LB)
agar medium (GIBCO BRL, Gaithersburg, MD). After overnight
culture at 37
 
8
 
C, white colonies were transferred into 96-well flat-
bottom plates containing 200 
 
m
 
l LB medium with 50 mg/liter of
ampicillin. Plates were incubated for an additional 18 h at 37
 
8
 
C
and several replicas of each plate were made. DNA was bound to
nitrocellulose (GIBCO BRL) by standard procedures followed by
hybridization with the appropriate V
 
a
 
 or CDR3 region–specific
probes. Oligonucleotide probes were endlabeled with the use of
 
g
 
-
 
32
 
ATP and T4 polynucleotide kinase. Hybridizations were per-
formed for 18 h at 37
 
8
 
C in a buffer containing 6 
 
3
 
 SSC/0.05%
pyrophosphate/5
 
3
 
 Denhardt/0.1mg/ml of denatured salmon
sperm DNA. After hybridizations filters were washed with 6 
 
3
 
SSC/0.05% pyrophosphate at 55–65
 
8
 
C and exposed on Kodak
film. TCR-
 
a
 
 CDR3 probe sequences were: patient Ob, Ob-
TDA 5
 
9 
 
- ACG GAC GCA ACC TCA GGA ACC TAC AAA
TAC - 3
 
9
 
; patient Hy, Hy-TDA 5
 
9
 
 - ACG GAC GCA GGA
GGT CAG AAT TTT GTC TTT - 39, Hy-TDT 59 - ACG
GAT ACA GGA GGA AGC TAC ATA CCT ACC - 39, Hy-
TDS 59 - GCT ACG GAC TCA GGA GGA AGC TAC ATA -
39; control Jl, Jl-SSI 59 - CTG AGT TCA ATT ATG GTG
GTG CTA CA - 39, Jl-SGS 59 - G GCT CTG AGT GGT TCT
AAC GAC - 39; control Nb, Nb-ASI 59 - TGT GCA GCA
AGT ATT AGT GAT GAC A - 39. TCR-b CDR3 probe se-
quences were: patient Hy, Hy-TDW 59 - ACT GAC TGG AGC
TCC TAC AAT GAG CA - 39, Hy-TSG 59 - ACT AGC GGC
TCC TAC AAT GAA CAG TTC TT - 39.
Specificity of Junctional Region Probes. The probes bound ex-
clusively to the sequences present in the original T cell clones.
cDNA from the original T cell clones were used to examine
probe hybridization conditions. The T cell clones Ob.1A12 and
Ob.2F3 from patient Ob differ by only three nucleotides in the N
region (one amino acid), sharing the same Va3.1 and Ja40 TCRs
(4). The probe specific for clone Ob.2F3 (Ob-TDA probe) hy-
bridized to Va3.1 amplified cDNA from that T cell clone, but
did not crosshybridize to Ob.1A12, thus demonstrating the probe’s
specificity. For patient Hy, two CDR3 region probes were de-
signed; one hybridized exclusively to the CDR3 region with an
Na-Ja region beginning with TDA (Hy-TDA probe), whereas the
other probe was designed to hybridize to the CDR3 region with
an Na-Ja region beginning with TDT (Hy-TDT probe). This
latter probe crosshybridized to the CDR3 region from another MBP
reactive T cell clone sequence with an Na-Ja region beginning with
TDS, which was a less frequently observed MBP-reactive T cell
clone in this patient. The CDR3 probes were specific for each pa-
tient as the probe from patient Ob did not hybridize with T cells
stimulated with MBPp85-99 from patient Hy and vice versa (data
not shown). The two Jl-SSI and Jl-SGS probes designed for iden-
tification of the different Va18-bearing clones of control Jl did
not crosshybridize, and the Nb-ASI probe for control Nb
MBPp85-99–reactive T cell clones similarly hybridized with the
appropriate TCR-a chain.
DNA Sequence Analysis. Bacterial colonies were expanded by
overnight culture in 3 ml of LB-ampicillin medium. Plasmids were
isolated using Magic minipreps as described by the manufacturer
(Promega Corp.). Double stranded DNA was sequenced using the
sequenase protocol (U.S. Biochem. Corp., Cleveland, OH) with
[35S]dATP as a radioactive tracer and the internal primer: 59 -
CTT GTC ACT GGA TTT AGA GTC TCT CAG CTG - 39
for TCR-a chain and 59 - TGT GCA CCT CCT TCC CAT
TCA CCC ACC AGC - 39 for TCR-b chain.1587 Bieganowska et al.
Culture of Whole Mononuclear Cells. Whole mononuclear cells
(WMNC) were separated by a Ficoll gradient centrifugation, and
106 cells were incubated in 24-well plates with either native peptide
MBPp85-99 (amino acid sequence ENPVVHFFKNIVTPR,
93K) or MBPp85-99 with amino acid substitutions at position 93
(93L, 93A, 93R, peptides synthesized by Biopolymer Laboratory,
Harvard Medical School) at a final concentration 10 mM, anti-CD3
mAb (OKT3, 1:1,000), or no stimuli in growth medium (RPMI
1640 medium supplemented with 10% autologous serum, 2 mM
l-glutamine, 10 mM Hepes 100 U/100 mg/ml penicillin/strepto-
mycin; all from BioWhittaker Inc., Walkersville, MD). After 7 d,
cells cultured with MBP peptides were restimulated with 106 an-
tigen-pulsed autologous blood WMNC prepared by incubating
autologous antigen-presenting cells with the appropriate peptide for
2 h followed by three washes in medium and irradiation (5,000
rads). On day 9, 10% IL-2 (Human T-Stim; Collaborative Bio-
medical Products, Bedford, MA) –containing medium was added to
each tube. On day 14, the cultures were harvested and mRNA was
extracted.
For estimating antigen-induced apoptosis, WMNC were cul-
tured for 72 h with 0, 0.5, 5, or 50 mM MBPp85-99 either with
control antibody alone (1,000 ng/ml isotype control antibody), or
with 500 or 1,000 ng/ml of anti-CD95 mAb (clone ZB4; Immu-
notech, supplied by Coulter Immunology, Hialeah, FL).
Cell Staining and Sorting. WMNC were incubated with mouse
anti–TCR Vb17.1 chain mAb (clone E17.5F3; Immunotech,
Westbrook, ME) for 30 min at 48C. Indirect staining was fol-
lowed by incubation with goat anti–mouse IgG and IgM Fab9
fragments conjugated with FITC (Tago Immunologicals, Cama-
rillo, CA). Anti-CD3 mAb and mouse IgG (both a gift from Coul-
ter Corp., Miami, FL) were used as positive and negative con-
trols. Vb17.1-positive and -negative populations were sorted on a
Coulter Sorter (type EPICS). For sorting IL-2Ra-positive and
IL-2Ra-negative T cell populations, WMNC were stained with
FITC-conjugated anti–IL-2Ra mAb (Coulter Corp.).
Single-sided PCR Amplification. The RNA pellet was resus-
pended in 18 ml of water and annealed with 15 ml oligo(dT) for
10 min at 708C. cDNA synthesis was performed in a reaction con-
taining 12 ml of 53 buffer, 6 ml of 0.1 M dithiothreithiol, 3 ml of
RNAsin, 5 ml of reverse transcriptase (all from Promega), and 3 ml of
dNTPs (Pharmacia, Uppsala, Sweden) for 1 h at 428C. cDNA was
precipitated with 1/10 volume of 3 M ammonium acetate and
2 volumes of ethanol at 2708C. The cDNA pellet was washed in
70% ethanol and air dried. Aliquots of cDNA were homopoly-
mer tailed with terminal deoxynucleotidyltransferase and deoxy-
cytosine triphosphate. Second strand synthesis was carried out
using Taq polymerase and an oligo-(dG) primer (59 - GATAGT-
CGACGGGGGGGGGG - 39).
Single Cell PCR. Single TCR-Vb17.1–expressing cells were
directly sorted onto V-bottom 96-well plates containing 150 ml of
PBS. Cells were then centrifuged and 5 ml of ddH2O was added
to each well followed by boiling for 5 min. First strand cDNA
synthesis was performed as described. The entire cDNA reaction
was used for the first 35 cycles of PCR with the Va3.1-specific
primer together with the Ca-specific primer. 2 ml of amplifica-
tion reaction was reamplified for the additional 35 cycles of PCR
with an internal Ca primer (59 - CTT GTC ACT GGA TTT AGA
GTC TCT CAG CTG - 39) and the same Va3.1-specific primer.
Spiking Experiment. Increasing numbers of the T cell clone
Hy1G11 were spiked into 500,000 WMNC from peripheral
blood of subject Ob resuspended in 1.0 ml of RPMI. The mRNA
was extracted and the frequency of Va3 transformants hybridiz-
ing to the Hy-TDT probe was measured as described above. The
frequency of Va3-positive T cells was measured by anchor PCR as
described above. The expected versus the measured frequency of
T cells expressing the Hy CDR3-TDT were plotted.
Results
Detection of Junctional Region Sequences Associated with
MBPp85-99 Recognition in Peripheral Blood T Cells. We an-
alyzed the TCR-a chain sequences of MBPp85-99–reactive
T cell clones isolated from the MS patients and normal
subjects. The MS patients chosen were those previously
shown to have clonally expanded and persistent MBPp85-
99–reactive T cells. The controls chosen had equal fre-
quencies of MBPp85-99–reactive T cell clones, as measured
by LDA (13). The MBPp85-99–reactive T cell clones stud-
ied from the MS patients used Va3.1 chains, whereas Va18
and Va8 chains were used in the T cell clones from the con-
trols. We measured the frequency of TCR-a sequences as-
sociated with MBPp85-99–reactive T cells directly in the
peripheral blood by PCR amplification of TCR-a chains
followed by subcloning and colony hybridization analysis.
Over 10,000 TCR-a transformants were screened for
binding of the Va- and CDR3-specific probes. Probes
were designed to bind the CDR3 coding regions of the
TCR-a chains under stringent hybridization conditions,
and the specificites of the probes were confirmed on the
original T cell clones. The CDR3 region probes were
named according to the first three amino acids in the NH2-
terminal sequence of the junctional region.
Using this approach, we could identify TCR-Va chains
expressed in MBPp85-99–reactive T cells in MS patients
(Table 1, Fig. 1 A). Specifically, the percentage of Va3.1-
positive transformants hybridizing with the Ob-TDA probe
was 0.8% of Va3.1 chains expressed in patient Ob; the per-
centages were 1.6% for probe Hy-TDA and 2.4% for probe
Hy-TDT of Va3.1 chains expressed in patient Hy (Table 1).
Repeated experiments measuring the percentage of trans-
formants hybridizing with either probe over a two-yr time
interval yielded similar frequencies (Table 1). As expected,
there was no crosshybridization of Hy probes with Ob
transformants or of Ob probes with Hy transformants. The
sequencing of 20 transformants expressing a TCR-a chain
that hybridized to the Ob-TDA probe in patient Ob and
25 transformants that hybridized to either the Hy-TDA or
Hy-TDT probes in patient Hy, demonstrated the same
TCR-a sequence as that expressed in the original MBP-
reactive T cell clones. As expected, DNA from 20 random
transformants that did not hybridize to the CDR3 probes
contained different TCR-a junctional region sequences. In
control subjects, after screening TCR-a transformants with
Jl-SSI and Jl-SGS probes for Jl and Nb-ASI probe for Nb,
we were unable to detect any sequences associated with rec-
ognition of MBPp85-99 in peripheral blood T cells (Table 1).
PCR Analysis of TCR Can Specifically Measure Clonal Ex-
pansion of Antigen-specific T Cells. It was important to show
that the assay could specifically detect antigen-induced
clonal expansion of T cells. This necessarily required in
vitro rather than in vivo experiments where WMNC were1588 Direct Analysis of Autoreactive T Cells in Autoimmune Disease
stimulated either nonspecifically by cross-linking the TCR
with anti-CD3 mAb or with the specific antigen MBPp85-
99. 14 d after stimulation with MBPp85-99, the percentage
of TCR-Va3.1 transformants expressing junctional region
sequences present in the specific MBPp85-99–reactive T cell
clones studied went from 0.8 to 90.2% in patient Ob and
from a total of 4.0 to 86.4% in patient Hy for Hy-TDA and
Hy-TDT sequences combined (Fig. 1 B and Table 2 A). This
increase was antigen specific as it was not seen upon anti-
body-mediated CD3 cross-linking. In contrast, none of
the previously observed TCR-a sequences expressed in
MBPp85-99–reactive T cell clones were found in controls
Nb and Jl.
A further control was performed to demonstrate the as-
say’s specificity and sensitivity. WMNC were stimulated with
either MBPp85-99 or with analogue peptides substituted at
position 93, a TCR contact residue. We found that while
stimulation of WMNC with the native peptide induced
marked increases in clonal expansion of the T cells as mea-
sured by the assay, stimulation of WMNC with MBPp85-
99 with a single amino acid substitution markedly dimin-
ishes this expansion (Table 2 B). Interestingly, these data
with PCR amplification and colony hybridization of mRNA
isolated after stimulation of WMNC with the analogue pep-
tides reflects experiments with in vitro culture of WMNC
with analogue peptides followed by T cell cloning. That is,
T cell clones generated with MBPp85-99 stimulation cross-
reacted with MBPp85-99 (93K®R) and (93K®L) pep-
tides, but not (93K®A) peptides (14). Furthermore, TCR
sequences of the T cell clones that were found to be cross-
reactive with the MBPp85-99(93R) and MBPp85-99(93L)
peptides used the Hy-TDS sequence that was also detected
in this assay using PCR amplification, followed by colony
hybridization. In total, these data demonstrate the very
high specificity of this assay in detecting antigen-specific
clonal expansion of peripheral blood T cells.
Estimation of the Total Frequency of MBPp85-99–Reactive T
Cells in Peripheral Blood. Assuming that each T cell ex-
pressing Va3.1 in the peripheral blood contributes equally to
the PCR amplification product using the Va3.1-Ca primer
pairs, the frequency of transformants with the TCR-a se-
quence associated with MBPp85-99 reactivity should reflect
the frequency of circulating T cells expressing that TCR-a
Figure 1. Frequency of TCR-Va3.1 transformants expressing the
CDR3 region sequence present in an MBPp85-99–reactive T cell clone
in MS patient Ob. (A) A representative experiment is shown, using mRNA
from peripheral blood lymphocytes. cDNA was synthesized and amplified
with Va3.1- and Ca-specific primers. PCR products were ligated into
pCRII vectors and competent Escherichia coli were transformed with liga-
tion products. Transformants were grown in 96-well plates and were trans-
ferred to nitrocellulose paper in duplicates. Blots were hybridized with either
Va3.1 probe (bottom) or a specific Ob-TDA probe recognizing TCR-
Va3.1 junctional region sequence expressed in a previously isolated
MBP-reactive T cell clone (top). (B) The same peripheral blood lympho-
cytes from subject Ob were stimulated with MBPp85-99 for 7 d, fol-
lowed by restimulation with antigen-pulsed WMNC and, on day 9, the
addition of IL-2. On day 14, mRNA was extracted from the antigen-
stimulated T cells and the proportion of transformants hybridizing with the
Ob-TDA–specific probe after Va3.1 chain amplification was measured.
Table 1. Frequency of CDR3-specific Sequences Associated
with MBPp85-99 Recognition in Unstimulated Peripheral
Blood Lymphocytes of MS Patients and Controls
Patient Ob
Va3.1
transformants
Ob-TDA*
transformants
1,173 9 (0.8%)
Patient Hy
Experiment
Va3.1
transformants
Hy-TDA*
transformants
Hy-TDT*
transformants
1 252 4 (1.6%) 6 (2.4%)
2 162 5 (3.1%) 10 (6.2%)
3 126 2 (1.6%) 2 (1.6%)
4 128 5 (3.9%) 2 (1.6%)
Control Jl
Va18
transformants
Jl-SSI
transformants
Jl-SGS
transformants
275 0 0
Control Nb
Va8
transformants
Nb-ASI
transformants
313 0
cDNA from unstimulated peripheral blood T cells from each subject
were amplified with their respective Va and Ca primers, and the puri-
fied PCR products ligated into pCRII vectors were used to transform
competent bacteria. Transformants were transferred to 96-well plates
containing medium and allowed to expand. Replicas of each trans-
formed colony were screened for binding to the respective TCR-Va
chain and the CDR3 region probe associated with TCR-Va chain
originating from an MBPp85-99–reactive T cell of that subject. *Total
of 19 transformants hybridizing to the correct CDR3 region were di-
rectly sequenced to confirm the correct identity of the TCR chain.1589 Bieganowska et al.
chain. To estimate the frequency of all T cells with the
TCR-a chain expressed in MBPp85-99–reactive T cells, it
was necessary to determine the proportion of T cells using
Va3.1 among all Va chains expressed. This was done by
amplifying TCR-a transcripts from WMNC using a mod-
ification of the rapid amplification of cDNA ends and an-
chored PCR methods. The percentage of Va3.1 chains
among all TCR-a chains in unstimulated WMNC was 5.1%
in patient Ob and 8.1% in patient Hy. The frequency of cir-
culating MBP-reactive T cells in unstimulated WMNC was
estimated by multiplying the frequency of Va3.1 among all
Va chains by the frequency of specific CDR3 sequences
expressed in the amplified TCR-Va3.1 chains associated
with recognition of MBPp85-99 (Table 1). Thus, the esti-
mated frequency of T cells recognizing MBPp85-99 in un-
stimulated WMNC of patient Ob was 3.9 3 1024 and in
patient Hy 3.2 3 1023 (1.3 3 1023 for the Hy-TDA se-
quence, and 1.9 3 1023 for the Hy-TDT sequence).
Pairing of TCR-a and -b Chains on T Cells Specific for
MBPp85-99. A series of experiments were performed to
determine whether expanded clonotypes bearing Hy-TDA
or Hy-TDT sequences are paired exclusively with Va3.1
and Vb17.1 chains as in the original MBPp85-99 reactive
clones. First, WMNC cultured for 14 d with MBPp85-99
were sorted into Vb17.1-positive and Vb17.1-negative pop-
ulations, and examined for expression of Va3.1-Hy-TDA
or Hy-TDT sequences. The same frequencies of Hy-TDA
and Hy-TDT sequences in the Vb17.1-positive population
(45.5% for TDA and 47.3% for TDT) and the unsorted
population were observed, while there were no Hy-TDA–
or Hy-TDT–detectable sequences in the Vb17.1-negative
population. These results indicated that after antigen stimu-
lation, TCR-Va3.1 chain Hy-TDA and Hy-TDT sequences
associated with MBPp85-99 reactivity are paired only with
Vb17.1 chains. Secondly, in the experiments using anchor
PCR in which all Va chains were amplified, CDR3 probes
recognizing sequences present in the TCR-Va3.1 chains
of MBP reactive T cell clones from both patients Hy and
Ob did not hybridize with transformants that expressed dif-
ferent Va chains (data not shown), confirming that the
Table 2. Frequency of CDR3-specific Sequences Associated with MBP Recognition After 14 d Stimulation of WMNC
A
Patient Ob
Va3.1
transformants
Ob-TDA
transformants*
Day 0 (unstimulated) 1173 9 (0.8%)
Day 14:
no antigen 118 0
MBPp85-99 164 148 (90.2%)
anti-CD3 84 0
Patient Hy
Va3.1
transformants
Hy-TDA*
transformants
Hy-TDT*
transformants
Hy-TDS*
transformants
Day 0 (unstimulated) 252 4 (1.6%) 6 (2.4%) –
Day 14:
no antigen 68 0 0 –
MPPp85-99 513 241 (47.0%) 202 (39.4%) –
anti-CD3 94 7 (7.4%) 0 –
B
Day 0 (unstimulated) 126 2 (1.6%) 2 (1.6%) 0
Day 14:
MBPp85-99 91 43 (47.2%) 13 (14.3%)) 1 (1.1%)
p85-99 (93L) 89 5 (5.6%) 2 (2.2%) 3 (3.4%)
p85-99 (93A) 92 1 (1.1%) 0 0
p85-99 (93R) 74 1 (1.3%) 0 7 (9.4%)
Stimulation of WMNC with (A) MBPp85-99, or anti-CD3 mAb and (B) MPBp85-99 peptides with substitutions at the TCR contact residue at po-
sition 93. WMNC were separated by a Ficoll gradient centrifugation, and 106 cells were incubated in 24-well plates with either native peptide
MBPp85-99 (amino acid sequence ENPVVHFFKNIVTPR, 93K) or MBPp85-99 with amino acid substitutions at position 93 (93L, 93A, 93R;
peptides synthesized by Biopolymer Laboratory, Harvard Medical School) at final concentration 10 mM, anti-CD3 mAb (OKT3, 1:1000), or no
stimuli in growth medium. On day 14, the cultures were harvested and mRNA was extracted. *Specificity of probe’s binding was verified by se-
quencing 11 of Ob-TDA–, 5 of Hy-TDA–, 5 of HY-TDT–, and 7 of Hy-TDS–positive transformants.1590 Direct Analysis of Autoreactive T Cells in Autoimmune Disease
CDR3 sequences are only associated with the Va3.1 chains.
Lastly, the definitive experiment to prove correct pairing of
TCR-a and -b chains associated with MBPp85-99 reac-
tivity before antigen stimulation required PCR amplifica-
tion of both TCR-a and -b chains from T cells isolated
directly from peripheral blood at limiting dilution. Our at-
tempts to simultaneously amplify Vb17.1 chains from the
same single cell expressing Va3.1 Hy-TDA and Hy-TDT
sequences were unsuccessful due to the lower efficiency of
the Vb17.1-Cb PCR despite multiple attempts to increase
the efficiency of the amplification procedure. However, this
analysis was successfully performed on Vb17.1-positive
cells sorted by flow cytometry at 10 cells/well where the
corresponding TCR-b chain sequence identified in the
previously isolated MBP reactive T cell clones (Vb17.1-TSG
sequence identified in clone Hy.1G11) was found with the
Va3.1 Hy-TDT sequence in the same well. In total, these
data strongly suggest that there is predominantly correct
pairing of TCR-a and -b chains associated with MBP-
reactive T cells isolated directly from peripheral blood.
Single Cell PCR of TCR-a Chain Sequences. A second ap-
proach was used to confirm the high frequencies of MBP-
p85-99–reactive T cells circulating in blood from subjects
with MS. Single T cells expressing Vb17.1 were sorted by
flow cytometry directly into single wells. PCR using semi-
nested primers for the Va3.1 chains followed by probing
with Hy-TDA– and Hy-TDT–labeled probes was performed
on each individual mRNA sample extracted from a single
T cell. Out of a total of 192 wells with single Vb17-posi-
tive T cells that were sorted by flow cytometry, 161 gave
an appropriate PCR product. 3 of the 161 single cells ana-
lyzed hybridized to the Hy-TDA probe and 1 hybridized
to the Hy-TDT probe (Table 3). The use of the correct
TCR-a chain in the Hy-TDT– or Hy-TDA–positive trans-
formants was confirmed by sequencing. As 5.3% of the
T cells expressed Vb17.1 as measured by flow cytometry, the
frequency of T cells expressing Vb17.1 chains and TCR-a
chain sequences found in MBPp85-99–reactive T cells was
calculated to be 1.3 3 1023 (for Hy-TDA and Hy-TDT
sequences combined), comparable to the 3.2 3 1023 calcu-
lated by examination of WMNC by PCR and colony hy-
bridization (Table 4). In total, these data confirm the high
frequency of circulating MBPp85-99–reactive T cells and
exclude the possibility that this was secondary to increased
amounts of TCR mRNA transcripts in activated MBPp85-
99–reactive T cells or to preferential amplification of the
particular Va chain.
Spiking Experiment. A third approach where MBP-reac-
tive T cells were spiked into peripheral blood T cells from
another subject was used to confirm the high frequencies of
MBP-reactive T cells observed in the blood. Increasing num-
bers of the T cell clone Hy1G11 were spiked into 500,000
WMNC from peripheral blood of subject Ob, mRNA was
extracted, and the frequency of Va3 transformants hybrid-
izing to the Hy-TDT probe measured. The frequency of
Va3-positive T cells measured by anchor PCR were mul-
tiplied by the percent of transformants that hybridized to
the Hy-TDT probe. A total of 795 Va3-positive transfor-
mants were analyzed at predicted frequencies between 2 3
1026 and 2 3 1022. The expected versus the measured fre-
quency of T cells expressing the Hy CDR3-TDT were
plotted (Fig. 2). At predicted frequencies of 2 x 1025, there
was no detectable hybridization to the 133 Va3 transfor-
mants examined. This likely represents the lower limit of
detection of the assay with examination of z125 transfor-
mants. The assay was less precise at a predicted frequency
of 2 3 1024 where sampling errors may occur; in this ex-
periment, there were 2 of 187 positive transformants. Al-
though at very high numbers of spiked T cell clones, the
assay may have slightly underestimated the frequency of
MBP-reactive T cells, at predicted frequencies of 2 3 1023
MBP-reactive T cells, which we observed in peripheral
blood of MS patients, the measured frequency in the spik-
ing assay was in close agreement (1.12 3 1023).
Fas-mediated Activation Induced Cell Death of IL-2Ra1
MBP-reactive T Cells There was an z1,000-fold higher
frequency of MBP-reactive T cells calculated by direct PCR
and colony hybridization as compared to LDA and these
data are summarized in Table 4. The high frequency of
MBP-reactive T cells in the peripheral blood of the pa-
tients with MS as compared to the normal individuals was
puzzling considering that the frequency of T cells as calcu-
lated by LDA was similar. These data suggested that the
frequency of MBP-reactive T cells as calculated by LDA
was accurate in the normal subjects, but may have been
grossly underestimated in the patients with MS. On the ba-
sis of findings that activated cells are more prone to anti-
gen-induced cell death (15), we hypothesized that subpop-
ulations of autoreactive T cells in patients with MS may
express IL-2Ra, and thus may undergo apoptosis in LDA
conditions leading to a lower calculated frequency. In this
regard, Pelfrey et al. have demonstrated that MBP-reactive
T cell lines from patients with MS are highly susceptible to
activation-induced cell death (16). The activation state of
MBPp85-99–reactive T cells could be examined by measur-
ing the frequency of TCR-Va3.1 transformants obtained
from IL-2Ra–positive and –negative populations that hy-
bridized to either the Hy-TDA or Hy-TDT probes. We
measured the distribution of Hy-TDA and Hy-TDT clono-
types in IL-2Ra–positive and –negative populations on two
different time points, 3 mo apart. On the first time point
Table 3. Single Cell PCR
Sorted populations
No. of transformants
expressing TCR-a 
(Hy-TDA)
sequence
No. of transformants
expressing TCR-a
(Hy-TDT)
sequence
Vb17.1 positive 3/161 1/161
Single T cells expressing Vb17.1 were sorted directly into 96-well
plates. PCR using seminested primers were performed on 161 wells.
Each well containing a PCR amplification product that hybridized to
the Hy-TDA or Hy-TDT probes was found to have a correct se-
quence.1591 Bieganowska et al.
tested, we found increased frequency of Hy-TDA se-
quence in IL-2Ra–positive population, whereas on the
second time point we could not detect any Va3.1 transfor-
mants expressing Hy-TDA sequence. In contrast, there was
an equal distribution of Va3.1 Hy-TDT sequence among
IL-2Ra–positive and –negative populations on the two
time points tested (Table 5).
To determine whether self antigen could induce selec-
tive loss of autoreactive T cells, WMNC were cultured with
increasing concentrations of MBPp85-99 peptide and the
frequency of TCR-Va3.1 transformants hybridizing to ei-
ther the Hy-TDA or Hy-TDT probes was measured be-
fore and after 72 h of culture. Note that the measurement
of Hy-CDR3 frequencies before incubation with MBP were
performed from three separate cultures and represent both
IL-2R–positive and –negative populations. There was an
almost total loss of transformants expressing the Hy-TDT se-
quence, whereas no changes were observed in transformants
expressing the Hy-TDA sequence (Fig. 3, A and B). Inter-
estingly, as described above, at this time point, Hy-TDA
sequence was only found in IL-2Ra–negative population.
Since it has been demonstrated that antigen stimulation of
activated T cells expressing IL-2Ra induces apoptosis me-
diated by expression of Fas (CD95) and Fas ligand on the
T cell surface (17–24), we examined whether antigen stim-
ulation of peripheral blood T cells in the presence of block-
ing anti-CD95 mAb selectively inhibited the loss of TCR-
Va3.1 Hy-TDT–expressing T cells. As shown in Fig. 3 B,
anti-CD95 mAbs totally blocked the MBPp85-99–induced
loss of transformants hybridizing to Hy-TDT probe while
having no effect on the frequency of Hy-TDA transfor-
mants. As T cells with the TCR-Va3.1–Hy-TDT sequence
expressed IL-2Ra, these data indicate that the low fre-
quency of MBPp85-99–reactive T cells as measured by
LDA was partly due to Fas-mediated apoptosis. The initia-
tion of immunotherapy that altered the frequency of MBP-
reactive T cells precluded this analysis of activated T cells in
subject Ob.
Discussion
We measured the frequency of clonally expanded and per-
sistent T cells recognizing the immunodominant MBPp85-
99 epitope in subjects with typical relapsing remitting MS.
Single T cells expressing mRNA transcripts encoding TCR-a
and -b chains found in T cell clones previously isolated
from these subjects recognizing the MBPp85-99 epitope
were examined. In contrast to frequencies of 1 in 105 to 106
as measured by LDA, estimates of the T cell frequencies ex-
pressing TCR chain transcripts associated with MBPp85-
99 recognition were as high as 1 in 300.
In retrospect, the high frequencies of MBPp85-99–reac-
tive T cells with presumed chronic stimulation is perhaps not
surprising. Subjects with HTLV-I and HIV infection have
Figure 2. Increasing numbers of the T cell clone Hy1G11 were spiked
into 500,000 WMNC from peripheral blood of subject Ob. The fre-
quency of Va3 transformants hybridizing to the Hy-TDT probe was mea-
sured and the expected versus the measured frequency of T cells express-
ing the Hy CDR3-TDT were plotted.
Table 4. Frequency of Circulating MBP-reactive T Cells in Patient Hy as Determined by Different Methodologies
Methodology
Estimated
frequency Calculation
PCR and colony hybridization of WMNC 3.2 3 1023* (Frequency of TCR-Va3.1 transformants calculated by anchor
PCR) 3 (frequency of TCR-Va3.1 transformants expressing
Hy-TDA and Hy-TDT sequences associated with 
MBPp85-99 reactivity)
PCR and colony hybridization of single 1.3 3 1023* (Frequency of Vb17.1-expressing T cells calculated by flow
Vb17.1-expressing T cells cytometry) 3 (frequency of single Vb17.1-expressing T cells
sorted by flow cytometry coexpressing TCR-Va3.1 Hy-TDA or TCR-Va3.1 Hy-TDT
sequences associated with MBPp85-99 reactivity)
Limiting dilution analysis
of WMNC stimulated with MBP 2.3 3 1026‡ Poisson frequency estimation
*Frequency of MBPp85-99–reactive T cells expressing Va3.1–Hy-TDA and Va3.1–Hy-TDT sequences.
‡Frequency of MBP-reactive T cells.1592 Direct Analysis of Autoreactive T Cells in Autoimmune Disease
high frequencies of virus reactive T cells as measured ex
vivo in peripheral blood using direct cytotoxicity assays (25–
27). In contrast, the LDA analysis of CTL frequencies in
HIV-infected patients which requires T cell expansion leads
to an 100-fold underestimate of CTL effector frequency.
Since direct cytotoxicity measurements do not require cell
growth, frequency measurements based on function would
not be affected by antigen-induced apoptosis.
McMichael and co-workers used a similar assay as re-
ported here to measure the frequencies of HIV gag–reactive
T cells as calculated by PCR analysis of TCR chains of HIV-
specific CTL clones. The frequency of HIV-reactive T cells
using direct cytotoxicity assays was almost identical to that
calculated by PCR, whereas the frequency as measured by
LDA underestimated the frequency of HIV-reactive T cells
(27). Moreover, the high frequency of HIV-reactive T cells
as measured by PCR was confirmed using multimeric pep-
tide–MHC complexes that bound antigen-specific T cells
(28). Specifically, MHC class I–A2 tetramers with HIV gag
or pol peptide were used to identify HIV specific CD81 in
seropositive donors. Flow cytometric analysis revealed a high
frequency of antigen specific CD81 cells (0.77%) that sup-
ported frequency estimation based on the PCR method.
Moreover, the high frequencies of MBPp85-99–reactive T
cells in the subjects with MS are similar to the frequencies
of cytochrome C reactive T cells calculated in mice using
direct PCR measurement after immunization with antigen
(29, 30). Thus, the frequency of circulating MBP-reactive
T cells in active MS patients appears to be on the same or-
der of magnitude as that observed with both MHC class I–
and II–restricted recall antigens.
The high frequency of MBP-reactive T cells may reflect
chronic stimulation of MBP-reactive T cells in the CNS. It
is also possible that repeated challenges by cross-reactive
microbes may induce selective T cell activation over time.
The MBP reactive T cell clones expressing different TCR-a
chains had similar dose response curves to MBPp85-99, yet
exhibited markedly different fine specificities for peptides
with different TCR contact residues. Moreover, these
MBPp85-99–reactive T cell clones have been shown to
recognize different cross-reactive viruses (31). Since only one
of the MBPp85-99–reactive T cell populations was acti-
vated on a second time point tested, as measured by IL-2Ra
chain expression, these data suggest that at this time point,
the MBPp85-99–reactive T cells expressing the Hy-TDT
CDR3 sequence were activated by a cross-reactive antigen
and not the native MBPp85-99 sequence. Fluctuation of
the MBPp85-99–specific clone with a CDR3-TDA sequence
among IL-2Ra–positive and –negative populations over a
time of 3 mo could also support such a possibility. Use of
this approach to examine other subjects over longer periods
of time may allow the determination of events that lead to
the activation of autoreactive T cells in humans.
Culture of peripheral blood T cells with MBPp85-99 ap-
Table 5. Distribution of Hy-TDT and Hy-TDA
Sequences Associated with MBP Recognition in IL-2Ra–negative
and –positive Populations
Probe
First time point Second time point
IL-2Ra2 IL-2Ra1 IL-2Ra2 IL-2Ra1
%%
CDR3-TDA 1.7 8.1 3.1 0
CDR3-TDT 3.4 3.0 6.6 4.7
IL-2Ra–negative and –positive populations were sorted on two time
points, 3 mo apart. WMNC were stained with FITC-conjugated anti–
IL2Ra mAb (Coulter Corp.) and IL-2Ra–positive and –negative T
cell populations were sorted. cDNA synthesis, PCR, and colony hy-
bridization were performed as described. A total of 1,152 TCR Va3.1
positive transformants were analyzed for binding of Hy-TDA and Hy-
TDT junctional region probes.
Figure 3. The percentage of
Va3.1 transformants hybridizing
to Hy-TDA and Hy-TDT
probes was determined on day 0
(prestimulation) and after 72 h of
culture with 0, 0.5, 5, or 50 mM
MBPp85-99 either with control
antibody alone (1,000 ng/ml iso-
type control antibody), or with
500 ng/ml or 1,000 ng/ml of
anti-CD95 mAb (clone ZB4;
Immunotech). (A) Frequency of
Hy-TDA–positive transformants
and (B) Hy-TDT–positive trans-
formants. A total of 1,660 transfor-
mants were analyzed. The day 0
prestimulation values were 1.1%
for Hy-TDA transformants and
3.4% for Hy-TDT transfor-
mants.1593 Bieganowska et al.
peared to induce Fas-mediated apoptosis of activated T cells.
In this regard, there was a modest, approximately threefold,
increase in the frequency of MBPp85-99–reactive T cells as
measured by LDA in preliminary experiments when cul-
tured in the presence of anti-CD95 mAb. While this may
partly explain the low frequency of antigen-reactive T cells as
measured by LDA, clearly other factors may also play a role.
For example, it is possible that subpopulations of MBPp85-
99–reactive T cells may represent regulatory T cells which
are difficult to grow (32). Changes in culture conditions with
the addition of other growth factors may also allow the ex-
pansion and measurement of greater numbers of circulating
autoreactive T cells.
In interpreting these data, it is important to point out the
limitations of extrapolating these data to all patients with
MS. Sophisticated immunologic experiments in humans are
greatly hampered by the outbred genotype of subjects. Thus,
specific primers and probes for TCRs must be generated
for each subject. Secondly, the patients with MS analyzed
in these experiments were selected for further investigation
because of previously demonstrated clonal expansion and
clonal persistence of MBP-reactive T cells, and we do not
believe that these data can be extrapolated to all subjects
with the disease. The two normal subjects also had demon-
strated the highest degree of clonal expansion observed in
any of our control subjects, albeit not to the same degree as
our subjects with MS (13). In fact, it is possible that MS is a
heterogeneous disease where different myelin antigens are
of importance in each individual. Nevertheless, these anal-
yses of MBP-reactive T cells provide the first direct evidence
for clonal expansion of MBP-reactive T cells in patients with
MS and demonstrate that direct amplification of TCR chains
can be used to quantitate circulating autoreactive T cells.
Moreover, these data demonstrate that at least a subpopula-
tion of patients with MS can have a very high frequency of
activated autoreactive T cells which undergo Fas-mediated
apoptosis upon antigen stimulation.
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